English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduMore patients than previously reported may experience hearing symptoms such as hearing loss or muffled hearing from a new treatment for thyroid eye disease, teprotumumab (Tepezza), according to a small study presented virtually at ENDO 2021, the Endocrine Society’s annual meeting.
Tag: thyroid eye disease
First FDA-approved drug for thyroid eye disease effective regardless of age, gender
Teprotumumab, the first FDA-approved medicine for thyroid eye disease, provides significant improvement in eye bulging, regardless of patient gender, age or smoking status, according to a study accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.